Other treatment options for CRC include targeted therapies against vascular endothelial growth factor (e.g. bevacizumab), and targeted therapies against epidermal growth factor receptor (EGFR) (e.g. cetuximab and panitumumab) which are only suitable for KRAS-wildtype metastatic CRC (mCRC)[33]. Here, KRAS is linked to colorectal carcinoma.